Credit Agricole Upgrades Bristol-Myers Squibb (BMY) Two Notches to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Price: $57.58 -2.6%
Rating Summary:
11 Buy, 23 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Rating Summary:
11 Buy, 23 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Join SI Premium – FREE
Credit Agricole upgraded Bristol-Myers Squibb (NYSE: BMY) from Underperform to Outperform, price target raised from $35 to $38.
For an analyst ratings summary and ratings history on Bristol-Myers Squibb click here. For more ratings news on Bristol-Myers Squibb click here.
Shares of Bristol-Myers Squibb closed at $34.16 yesterday.
For an analyst ratings summary and ratings history on Bristol-Myers Squibb click here. For more ratings news on Bristol-Myers Squibb click here.
Shares of Bristol-Myers Squibb closed at $34.16 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Upgrades Tyler Tech (TYL) to Overweight
- Wells Fargo Upgrades Allstate (ALL) to Equal Weight
- Bristol Myers Squibb stock surges on dual phase 3 clinical trial successes
Create E-mail Alert Related Categories
UpgradesRelated Entities
Credit AgricoleSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
